BRPI1015338A2 - formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento - Google Patents

formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento

Info

Publication number: BRPI1015338A2
Authority: BR; Brazil
Prior art keywords: salt; compound; drip; aggregate; disease
Prior art date: 2009-04-24

Application number

BRPI1015338A

Other languages

English (en)

Inventor

Heidi Lopez De Diego

Svend Treppendahl

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-24

Filing date

2010-04-16

Publication date

2016-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015338(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-16 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2016-05-31 Publication of BRPI1015338A2 publication Critical patent/BRPI1015338A2/pt

2021-01-05 Publication of BRPI1015338B1 publication Critical patent/BRPI1015338B1/pt

2021-05-25 Publication of BRPI1015338B8 publication Critical patent/BRPI1015338B8/pt

2021-08-10 Publication of BRPI1015338C1 publication Critical patent/BRPI1015338C1/pt

Links

150000001875 compounds Chemical class 0.000 title 2
150000003839 salts Chemical class 0.000 title 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000007788 liquid Substances 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Lubricants (AREA)

BRPI1015338A 2009-04-24 2010-04-16 formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento BRPI1015338C1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200900531		2009-04-24
DKPA200900531		2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en)	2009-04-24	2010-04-16	Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (4)

Publication Number	Publication Date
BRPI1015338A2 true BRPI1015338A2 (pt)	2016-05-31
BRPI1015338B1 BRPI1015338B1 (pt)	2021-01-05
BRPI1015338B8 BRPI1015338B8 (pt)	2021-05-25
BRPI1015338C1 BRPI1015338C1 (pt)	2021-08-10

Family

ID=42669509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1015338A BRPI1015338C1 (pt)	2009-04-24	2010-04-16	formulação farmacêutica líquida, uso de um sal, composto e recipiente equipado com um agregado de gotejamento

Country Status (35)

Country	Link
US (4)	US8940746B2 (pt)
EP (1)	EP2421534B1 (pt)
JP (1)	JP5722879B2 (pt)
KR (1)	KR101779214B1 (pt)
CN (2)	CN104693145A (pt)
AR (2)	AR076400A1 (pt)
AU (1)	AU2010238946B2 (pt)
BR (1)	BRPI1015338C1 (pt)
CA (1)	CA2759456C (pt)
CL (1)	CL2011002631A1 (pt)
CO (1)	CO6450649A2 (pt)
CR (1)	CR20110554A (pt)
DK (1)	DK2421534T3 (pt)
DO (2)	DOP2011000319A (pt)
EA (1)	EA021122B1 (pt)
ES (1)	ES2512719T3 (pt)
GE (1)	GEP20135938B (pt)
HK (1)	HK1206732A1 (pt)
HR (1)	HRP20140880T1 (pt)
IL (1)	IL215362A0 (pt)
MA (1)	MA33298B1 (pt)
MX (1)	MX2011011119A (pt)
MY (1)	MY155288A (pt)
NZ (1)	NZ596431A (pt)
PL (1)	PL2421534T3 (pt)
PT (1)	PT2421534E (pt)
RS (1)	RS53539B1 (pt)
SG (1)	SG175124A1 (pt)
SI (1)	SI2421534T1 (pt)
SM (1)	SMT201400159B (pt)
TN (1)	TN2011000504A1 (pt)
TW (1)	TWI461224B (pt)
UA (1)	UA106985C2 (pt)
WO (1)	WO2010121621A1 (pt)
ZA (1)	ZA201107731B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG175124A1 (en)	2009-04-24	2011-12-29	Lundbeck & Co As H	Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
WO2014044721A1 (en)	2012-09-19	2014-03-27	Sandoz Ag	Novel crystalline form of vortioxetine hydrobromide
AU2014286308B2 (en) *	2013-07-01	2018-05-10	Lek Pharmaceuticals D.D.	1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
CN106103418A (zh)	2014-01-31	2016-11-09	埃吉斯药物私人有限公司	沃替西汀盐的制备方法
CN104146953A (zh) *	2014-07-24	2014-11-19	李雪梅	一种氢溴酸沃替西汀注射液
CN104119298B (zh) *	2014-08-13	2016-08-24	北京蓝贝望生物医药科技股份有限公司	氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) *	2014-08-13	2016-08-17	北京蓝贝望生物医药科技股份有限公司	沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en)	2014-10-29	2014-12-10	Therakind Ltd	Formulations
WO2016125190A2 (en)	2015-02-04	2016-08-11	Mylan Laboratories Limited	Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) *	2015-05-13	2020-07-05	H Lundbeck As	فيروتيوكسيتين بيروجلوتامات
JP6987064B2 (ja)	2016-02-08	2021-12-22	ハー・ルンドベック・アクチエゼルスカベット	１−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの合成
WO2018002115A1 (en)	2016-07-01	2018-01-04	H. Lundbeck A/S	Vortioxetine dosing regimes for fast onset of antidepressant effect
CN106518807A (zh) *	2016-09-17	2017-03-22	北京万全德众医药生物技术有限公司	乳酸沃替西汀晶型的制备方法
US10519121B2 (en)	2016-12-30	2019-12-31	Apicore Us Llc	Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) *	2017-03-10	2017-08-04	万全万特制药（厦门）有限公司	沃替西汀β晶型的制备方法
GB2564887A (en) *	2017-07-26	2019-01-30	Azad Pharmaceutical Ingredients Ag	New route of synthesis to vortioxetine salts
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP2023520016A (ja)	2020-04-03	2023-05-15	ハー・ルンドベック・アクチエゼルスカベット	感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
EP4681702A1 (en) *	2024-07-16	2026-01-21	PharmaPath S.A.	Oral solution comprising vortioxetine hydrobromide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2004087156A1 (en)	2003-04-04	2004-10-14	H. Lundbeck A/S	4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
CA2656057C (en) *	2006-06-16	2012-10-02	H. Lundbeck A/S	Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PL2044043T5 (pl) *	2006-06-16	2022-05-02	H. Lundbeck A/S	Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TWI405588B (zh)	2007-03-20	2013-08-21	Lundbeck & Co As H	４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) *	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
SG175124A1 (en)	2009-04-24	2011-12-29	Lundbeck & Co As H	Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

2010
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 RS RSP20140505 patent/RS53539B1/sr unknown
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active Active
- 2010-04-16 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en not_active Ceased
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
2014
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CR20110554A (es)	2012-02-14
BRPI1015338B8 (pt)	2021-05-25
KR101779214B1 (ko)	2017-09-18
BRPI1015338B1 (pt)	2021-01-05
PT2421534E (pt)	2014-10-29
EP2421534A1 (en)	2012-02-29
CN104693145A (zh)	2015-06-10
CO6450649A2 (es)	2012-05-31
BRPI1015338C1 (pt)	2021-08-10
CN102405048A (zh)	2012-04-04
UA106985C2 (uk)	2014-11-10
HRP20140880T1 (hr)	2014-11-07
US20120035188A1 (en)	2012-02-09
EA201171287A1 (ru)	2012-04-30
AU2010238946A1 (en)	2011-12-08
ZA201107731B (en)	2013-02-27
US10857149B2 (en)	2020-12-08
RS53539B1 (sr)	2015-02-27
EA021122B1 (ru)	2015-04-30
CA2759456A1 (en)	2010-10-28
US9475748B2 (en)	2016-10-25
EP2421534B1 (en)	2014-09-03
DOP2012000211A (es)	2013-03-31
SG175124A1 (en)	2011-12-29
MX2011011119A (es)	2011-11-04
CL2011002631A1 (es)	2012-04-09
AR076400A1 (es)	2011-06-08
NZ596431A (en)	2012-12-21
US20190167667A1 (en)	2019-06-06
WO2010121621A1 (en)	2010-10-28
IL215362A0 (en)	2011-12-29
US20170224677A1 (en)	2017-08-10
CA2759456C (en)	2017-10-31
SI2421534T1 (sl)	2014-11-28
DOP2011000319A (es)	2012-02-29
AR122051A2 (es)	2022-08-10
JP5722879B2 (ja)	2015-05-27
TN2011000504A1 (en)	2013-05-24
GEP20135938B (en)	2013-10-10
ES2512719T3 (es)	2014-10-24
MA33298B1 (fr)	2012-05-02
TWI461224B (zh)	2014-11-21
AU2010238946B2 (en)	2013-03-28
JP2012524735A (ja)	2012-10-18
PL2421534T3 (pl)	2014-12-31
US8940746B2 (en)	2015-01-27
KR20120022809A (ko)	2012-03-12
HK1206732A1 (en)	2016-01-15
DK2421534T3 (da)	2014-10-13
US10034876B2 (en)	2018-07-31
US20150094316A1 (en)	2015-04-02
TW201041604A (en)	2010-12-01
MY155288A (en)	2015-09-30
SMT201400159B (it)	2015-01-15

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-09-17	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-07-07	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-10-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-11-24	B09X	Republication of the decision to grant [chapter 9.1.3 patent gazette]
2021-01-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-08-10	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2609 DE 05/01/2021 QUANTO A QUALIFICACAO DO TITULAR.

Publication	Publication Date	Title
BRPI1015338A2 (pt)	2016-05-31	formulação farmacêutica líquida, método para o tratamento de uma doença, uso de um sal, sal de um composto, composto, recipiente equipado com um agregado de gotejamento
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112012005853A2 (pt)	2017-06-06	aplicador automático para preparações farmacêuticas líquidas, particularmente para insulina
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0908972A2 (pt)	2015-07-28	Cartucho para preparação de um líquido compreendendo uma parede de distribuição perfurável
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014003681A8 (pt)	2018-01-23	composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112014010183A2 (pt)	2017-05-02	composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
BRPI1012276A2 (pt)	2016-03-29	"dispositivo para distribuir medicamento líquido."
BR112013020352A2 (pt)	2017-08-08	composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BRPI0809674A2 (pt)	2014-10-07	Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5
BR112014007134A2 (pt)	2017-12-19	usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112014010179A2 (pt)	2017-04-25	composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112014016287A2 (pt)	2017-07-04	composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
BRPI0912348A2 (pt)	2015-10-13	composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BR112014014769A2 (pt)	2017-06-13	Composto, composição farmacêutica, e, uso de um composto ou sal.
HUE046557T2 (hu)	2020-03-30	Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
IL258357A (en)	2018-05-31	A semi-solid aqueous pharmaceutical preparation containing tapentadol
BR112014006420A2 (pt)	2017-04-11	compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
BR112013013522A2 (pt)	2019-09-24	polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
BR112013031712A2 (pt)	2017-07-04	composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BRPI1010300A2 (pt)	2017-05-16	processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica.
BRPI1007624A2 (pt)	2016-07-26	composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
BR112014008241A2 (pt)	2017-04-18	composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto